Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02145078 · ClinicalTrials.gov registry record · NA
Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer
A NA study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT02145078 is a NA study that was terminated before completion, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 4 participants.
The verdict
NCT02145078, a NA study, was terminated before completion, sponsored by Barbara Ann Karmanos Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This pilot clinical trial studies whether the levels of certain genes in the tissue and blood are related to how well patients with stage IV non-small cell lung cancer respond to chemotherapy. Genes may affect how sensitive or resistant tumors are to chemotherapy. Studying the levels of genes related to tumor response before and after chemotherapy may help doctors learn whether they can predict how well patients will respond to treatment.
Interventions
- OTHER laboratory biomarker analysis
- DRUG docetaxel
- DRUG gemcitabine hydrochloride
- DRUG pemetrexed disodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2014-06 |
| Est. Completion | 2017-03-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02145078
The ClinicalTrials.gov registry entry for NCT02145078 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT02145078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02145078 about?
NCT02145078 is a clinical study titled "Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer". This pilot clinical trial studies whether the levels of certain genes in the tissue and blood are related to how well patients with stage IV non-small cell lung cancer respond to chemotherapy. Genes may affect how sensitive or resistant tumors are to chemotherapy. Studying the levels of genes relate...
What is the current status of trial NCT02145078?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2014-06. Estimated completion is 2017-03-07.
What interventions are being tested in trial NCT02145078?
The interventions under investigation include: laboratory biomarker analysis (OTHER), docetaxel (DRUG), gemcitabine hydrochloride (DRUG), pemetrexed disodium (DRUG).
Who is sponsoring clinical trial NCT02145078?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.